Analysts Offer Predictions for CADL FY2030 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Candel Therapeutics in a research note issued to investors on Thursday, March 12th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of $2.91 for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.47) per share.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.30).

Several other equities analysts have also commented on CADL. Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Candel Therapeutics in a research report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Wednesday, January 21st. Stephens restated an “overweight” rating and set a $15.00 price objective on shares of Candel Therapeutics in a report on Monday, December 8th. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Citigroup reduced their target price on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Candel Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Candel Therapeutics Price Performance

CADL opened at $5.17 on Monday. Candel Therapeutics has a 1 year low of $4.25 and a 1 year high of $9.08. The company’s 50 day simple moving average is $5.58 and its 200 day simple moving average is $5.41. The stock has a market capitalization of $283.83 million, a PE ratio of -7.28 and a beta of -0.91. The company has a debt-to-equity ratio of 0.91, a quick ratio of 13.49 and a current ratio of 13.49.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Moneta Group Investment Advisors LLC raised its holdings in shares of Candel Therapeutics by 4.9% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock valued at $240,000 after purchasing an additional 2,000 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Candel Therapeutics by 29.0% in the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock valued at $85,000 after purchasing an additional 3,380 shares during the last quarter. Taylor Financial Group Inc. boosted its holdings in Candel Therapeutics by 36.0% in the third quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company’s stock worth $69,000 after purchasing an additional 3,600 shares in the last quarter. MetLife Investment Management LLC increased its position in Candel Therapeutics by 25.5% during the fourth quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock worth $110,000 after buying an additional 3,955 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after buying an additional 4,439 shares during the last quarter. Institutional investors and hedge funds own 13.93% of the company’s stock.

Insider Buying and Selling

In other Candel Therapeutics news, Director Paul B. Manning acquired 550,458 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were purchased at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the completion of the transaction, the director owned 2,763,527 shares in the company, valued at $15,061,222.15. The trade was a 24.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 16.60% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.